fasudil has been researched along with Dyslipidemias in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Present study was conducted to investigate the effects of rosuvastatin combined with fasudil on rabbits with dyslipidemia." | 7.81 | Effects of rosuvastatin combined with fasudil therapy on rabbits with dyslipidemia. ( Li, Z; Lian, H; Liang, Q; Zeng, F; Zheng, D, 2015) |
| "Present study was conducted to investigate the effects of rosuvastatin combined with fasudil on rabbits with dyslipidemia." | 3.81 | Effects of rosuvastatin combined with fasudil therapy on rabbits with dyslipidemia. ( Li, Z; Lian, H; Liang, Q; Zeng, F; Zheng, D, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z | 1 |
| Lian, H | 1 |
| Liang, Q | 1 |
| Zeng, F | 1 |
| Zheng, D | 1 |
1 other study available for fasudil and Dyslipidemias
| Article | Year |
|---|---|
Effects of rosuvastatin combined with fasudil therapy on rabbits with dyslipidemia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Drug Therapy, Combination; Dyslipidemias; Ma | 2015 |